01
Solid state research

Experimental solid-state R&D for the future of drug development

02
Overview

Solid-state research services from pre-clinical to NDA

Our experimental services cover the entire spectrum of solid-state research, guiding projects from pre-clinical stages through to NDA filing. We focus on delivering a seamless and comprehensive drug development process, enhancing pharmaceutical R&D efficiency and ensuring success at every regulatory phase.
Research services
  • Polymorph/Salt/Cocrystal screening & assessment
  • Crystallization process development
  • Solid dispersion formulation development
  • Solid state characterization, & analytical method development
03
Automated Solid Form Screening and Selection

R&D with solid-state chemistry screening platform

The intelligent automated solid-state screening platform transforms pharmaceutical R&D by integrating experimental techniques with automation. This approach reduces costs, boosts productivity, and accelerates the research and development process for faster results.
solid form developability evaluation
Comprehensive polymorph screening identifies and analyzes different crystal forms
Salt and co-crystal screening improves drug stability and solubility
Assessment of solid form developability includes evaluating solubility, stability, and hygroscopicity
Solid form analysis ensures intellectual property protection and supports regulatory submissions
Enhancement of drug bioavailability and key physicochemical properties
04
Crystallization process development

Optimizing drug properties through crystallization process development

Crystallization process development enhances the properties of active pharmaceutical ingredients (APIs) by improving particle-size distribution, crystal morphology, bulk properties, and flowability. These improvements lead to better processability and dissolution of drugs, ensuring more efficient production and enhanced performance.
Scenarios 01
Improving Powder Properties
Powder properties are enhanced to improve drug performance and manufacturability.
Scenarios 02
Preparing Meta-Stable Forms
Meta-stable forms are prepared to optimize drug stability and efficacy.
Scenarios 03
Kilogram-Scale Crystallization
Crystallization processes are developed at kilogram scale to meet production demands.
05
Amorphous solid dispersion formulation development

Enhancing drug solubility with amorphous solid dispersion

Technologies like spray drying are used to disperse insoluble drugs in carrier polymer materials, improving solubility. These polymers are carefully screened to ensure the amorphous solid dispersion meets strict stability and dissolution performance standards, even at gram scale. This process enhances drug efficacy and ensures reliable production quality.